Literature DB >> 34052296

Dimethyl fumarate abridged tauo-/amyloidopathy in a D-Galactose/ovariectomy-induced Alzheimer's-like disease: Modulation of AMPK/SIRT-1, AKT/CREB/BDNF, AKT/GSK-3β, adiponectin/Adipo1R, and NF-κB/IL-1β/ROS trajectories.

Israa M Abd El-Fatah1, Heba M A Abdelrazek2, Sherehan M Ibrahim1, Dalaal M Abdallah3, Hanan S El-Abhar1.   

Abstract

Since the role of estrogen in postmenauposal-associated dementia is still debatable, this issue urges the search for other medications. Dimethyl fumarate (DMF) is a drug used for the treatment of multiple sclerosis and has shown a neuroprotective effect against other neurodegenerative diseases. Accordingly, the present study aimed to evaluate the effect of DMF on an experimental model of Alzheimer disease (AD) using D-galactose (D-Gal) administered to ovariectomized (OVX) rats, resembling a postmenopausal dementia paradigm. Adult 18-month old female Wistar rats were allocated into sham-operated and OVX/D-Gal groups that were either left untreated or treated with DMF for 56 days starting three weeks after sham-operation or ovariectomy. DMF succeeded to ameliorate cognitive (learning/short- and long-term memory) deficits and to enhance the dampened overall activity (NOR, Barnes-/Y-maze tests). These behavioral upturns were associated with increased intact neurons (Nissl stain) and a reduction in OVX/D-Gal-mediated hippocampal CA1 neurodegeneration and astrocyte activation assessed as GFAP immunoreactivity. Mechanistically, DMF suppressed the hippocampal contents of AD-surrogate markers; viz., apolipoprotein (APO)-E1, BACE1, Aβ42, and hyperphosphorylated Tau. Additionally, DMF has augmented the neuroprotective parameters p-AKT, its downstream target CREB and BDNF. Besides, it activated AMPK, and enhanced SIRT-1, as well as antioxidant defenses (SOD, GSH). On the other hand, DMF inhibited the transcription factor NF-κB, IL-1β, adiponectin/adiponectin receptor type (AdipoR)1, GSK-3β, and MDA. Accordingly, in this postmenopausal AD model, DMF treatment by pursuing the adiponectin/AdipoR1, AMPK/SIRT-1, AKT/CREB/BDNF, AKT/GSK-3β, and APO-E1 quartet hampered the associated tauo-/amyloidopathy and NF-κB-mediated oxidative/inflammatory responses to advance insights into its anti-amnesic effect.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  APO-E1; BACE1; Barnes-/Y-maze tests; GFAP; Novel object recognition test

Mesh:

Substances:

Year:  2021        PMID: 34052296     DOI: 10.1016/j.neuint.2021.105082

Source DB:  PubMed          Journal:  Neurochem Int        ISSN: 0197-0186            Impact factor:   3.921


  4 in total

1.  Bupivacaine reduces GlyT1 expression by potentiating the p-AMPKα/BDNF signalling pathway in spinal astrocytes of rats.

Authors:  Jianqiang Yu; Hanxiang Ma; Kaimei Lu; Liyan Zhao; Yonghai Zhang; Fan Yang; Huiwen Zhang; Jie Wang; Bin Li; Guimei Ji
Journal:  Sci Rep       Date:  2022-01-26       Impact factor: 4.379

2.  Dimethyl fumarate improves cognitive impairment by enhancing hippocampal brain-derived neurotrophic factor levels in hypothyroid rats.

Authors:  Haiyan Pan; Yanbo Wang; Xiaowei Wang; Ci Yan
Journal:  BMC Endocr Disord       Date:  2022-07-22       Impact factor: 3.263

Review 3.  Sirtuins functions in central nervous system cells under neurological disorders.

Authors:  Jing Yan; Xiaole Tang; Zhi-Qiang Zhou; Jie Zhang; Yilin Zhao; Shiyong Li; Ailin Luo
Journal:  Front Physiol       Date:  2022-08-30       Impact factor: 4.755

Review 4.  Mitochondrial dysfunction in microglia: a novel perspective for pathogenesis of Alzheimer's disease.

Authors:  Yun Li; Xiaohuan Xia; Yi Wang; Jialin C Zheng
Journal:  J Neuroinflammation       Date:  2022-10-06       Impact factor: 9.587

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.